ArticleJCI insight2016
Recognition of influenza H3N2 variant virus by human neutralizing antibodies.
Article in JCI insight, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Localized adaptive evolution in VP1 drives antigenic divergence of feline calicivirus despite high sequence conservation.Veterinary research · 2026Article
- A protective and heterosubtypic antibody lineage targeting the influenza A virus neuraminidase active site.The Journal of clinical investigation · 2025Article
- Emerging and Pandemic Pathogens: Lessons Learned From a Clinical Research Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Review
- Monoclonal antibodies: From magic bullet to precision weapon.Molecular biomedicine · 2024Review
- Monoclonal antibody therapeutics for infectious diseases: Beyond normal human immunoglobulin.Pharmacology & therapeutics · 2022Review
- Article
- Mapping of a Novel H3-Specific Broadly Neutralizing Monoclonal Antibody Targeting the Hemagglutinin Globular Head Isolated from an Elite Influenza Virus-Immunized Donor Exhibiting Serological Breadth.Journal of virology · 2020Article
- Influenza Hemagglutinin Nanoparticle Vaccine Elicits Broadly Neutralizing Antibodies against Structurally Distinct Domains of H3N2 HA.Vaccines · 2020Article
- HumanmBio · 2019Article
- A Site of Vulnerability on the Influenza Virus Hemagglutinin Head Domain Trimer Interface.Cell · 2019Article
- Antibody Determinants of Influenza Immunity.The Journal of infectious diseases · 2019Article
- A multifunctional human monoclonal neutralizing antibody that targets a unique conserved epitope on influenza HA.Nature communications · 2018Article
- Neutrophils are essential for induction of vaccine-like effects by antiviral monoclonal antibody immunotherapies.JCI insight · 2018Article
- Passive immunization with influenza haemagglutinin specific monoclonal antibodies.Human vaccines & immunotherapeutics · 2018Article
- Principles of Broad and Potent Antiviral Human Antibodies: Insights for Vaccine Design.Cell host & microbe · 2017Review
- Amino Acids in Hemagglutinin Antigenic Site B Determine Antigenic and Receptor Binding Differences between A(H3N2)v and Ancestral Seasonal H3N2 Influenza Viruses.Journal of virology · 2017Article
- Heterologous prime-boost vaccination with H3N2 influenza viruses of swine favors cross-clade antibody responses and protection.NPJ vaccines · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Since 2011, over 300 human cases of infection, especially in exposed children, with the influenza A H3N2 variant (H3N2v) virus that circulates in swine in the US have been reported. The structural and genetic basis for the lack of protection against H3N2v induced by vaccines containing seasonal H3N2 antigens is poorly understood. We isolated 17 human monoclonal antibodies (mAbs) that neutralized H3N2v virus from subjects experimentally immunized with an H3N2v candidate vaccine. Six mAbs exhibited very potent neutralizing activity (IC
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.